Sepsis in the immunocompromised host
Bedside summary
Immunosuppression (neutropenia, chemotherapy, high-dose steroids, transplant/calcineurin inhibitors, biologics such as rituximab, asplenia, HIV, myeloma) both raises infection risk and BLUNTS the presentation — fever or subtle deterioration may be the only sign, and classic localising features are muted. The likely pathogens, and therefore the empirical regimen, depend on WHICH arm of immunity is impaired.
Red flags
- Fever or unexplained deterioration in a neutropenic/immunosuppressed patient
- Neutrophils < 0.5 ×10⁹/L (or expected to fall), especially prolonged
- Septic shock / rising lactate
- New respiratory failure (consider PJP, mould, viral)
- Indwelling line as a source
Assessment
Differential diagnosis
- Non-infective causes of fever (drug, tumour, transfusion, GVHD, engraftment)
- Venous thromboembolism
- Adrenal insufficiency
- Transplant rejection
- Cytokine-release / immunotherapy toxicity
Investigations
- Full septic screen without delaying antibiotics: blood cultures (peripheral + each lumen of any line), lactate, FBC + differential (degree/duration of neutropenia), U&E, LFTs, CRP/procalcitonin, urine, CXR
- Targeted work-up by defect: fungal markers (β-D-glucan/galactomannan), respiratory viral PCR, CMV, PJP (induced sputum/BAL), and cross-sectional imaging with a low threshold
- Line/site assessment for source; consider LP/CT per focus
Management
- Treat as a time-critical emergency: EARLY broad-spectrum EMPIRICAL antibiotics (within ~1 h) after cultures — do NOT wait for a source; blunted signs under-call severity.
- FEBRILE NEUTROPENIA → an anti-pseudomonal β-lactam (piperacillin-tazobactam, cefepime, or a carbapenem) as first-line; add vancomycin for line/skin/soft-tissue or septic-shock risk.
- Tailor to the immune defect: innate/neutropenic → cover Gram-negatives (incl. Pseudomonas) + Gram-positives and consider EARLY antifungals if persistently febrile; T-cell defect (transplant/HIV) → add cover for opportunistic/viral/intracellular (PJP, CMV, TB); humoral/asplenia → cover encapsulated organisms (pneumococcus, meningococcus, Hib), consider IVIG.
- Run the Surviving Sepsis bundle: fluids, lactate, vasopressors for shock, and prompt SOURCE CONTROL (remove/exchange an infected line; drain collections).
- Involve haematology/oncology, infectious diseases and transplant teams early; consider G-CSF and adjust immunosuppression with their guidance.
- Reassess at 48–72 h with culture results; de-escalate or broaden (add antifungal/antiviral) driven by the clinical course and the specific deficit.
Drugs & doses
Disposition
Complications & pitfalls
- Rapid progression to septic shock and multi-organ failure
- Invasive fungal disease
- Opportunistic infection (PJP, CMV, TB)
- Line-associated bacteraemia
- Higher mortality than in immunocompetent sepsis
Exam pearls
- A blunted inflammatory response hides severity — treat fever in the immunocompromised as sepsis until proven otherwise.
- Match the empirical regimen to the immune DEFECT: neutropenia → bacteria/fungi; T-cell → viral/opportunistic; humoral/asplenia → encapsulated organisms.
- Do not delay antibiotics for imaging or a source — minutes matter in febrile neutropenia.
- Source control (the line) is as important as the antibiotic.
Fever or subtle decline in an immunosuppressed patient is a sepsis emergency: cultures then EARLY broad empirical antibiotics (anti-pseudomonal ± vancomycin for febrile neutropenia), a regimen matched to the immune defect, full sepsis bundle with source control, and early specialist input.
Disclaimer: Educational decision support for qualified clinicians and students — not a substitute for clinical judgement, local protocols or a full drug reference. Confirm every dose and contraindication against your formulary before prescribing.